// App-Quantinova.ai

1669 : PI3K/AKT/mTOR Signaling Is a Significant Druggable Pathway In Infant Acute Lymphoblastic Leukemia (ALL)

Researchers

Presenter

  • Karen A. Urtishak

Principal Investigators

  • Wang Li-San

  • David T. Teachey

  • Cheryl L. Willman

  • Carolyn A. Felix

  • Sarah K. Tasian

  • Jeffrey S. Barrett

  • I-Ming L. Chen

  • Susan R. Atlas

  • Richard C. Harvey

  • Nyla A. Heerema

  • Andrew J. Carroll

  • Stephen P. Hunger

Medical Centers

  • Physics and Astronomy, University of New Mexico, Albuquerque, NM

  • Pediatric Hematology/Oncology/BMT, University of Colorado School of Medicine and Children's Hospital Colorado, Aurora, CO

  • Cancer Center/Pathology, University of New Mexico, Albuquerque, NM

  • Department of Pathology, The Ohio State University, Columbus, OH

  • University of New Mexico Cancer Center, Albuquerque, NM

  • Department of Clinical Pharmacology and Therapeutics, The Childre-s Hospital of Philadelphia Research Institute, Philadelphia, PA

  • Department of Radiation Oncology, University of Alabama at Birmingham, Birmingham, AL

  • Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA

  • Department of Pathology, The Children's Hospital of Philadelphia, Philadelphia, PA

  • The Childrens Hospital of Philadelphia and The University of Pennsylvania Perelman School of Medicine, Philadelphia, PA

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

  • Solid malignancies

Biomarkers

  • Breakpoint Cluster Region

  • p70S6 kinase

  • Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform

  • Serine/threonine-protein kinase mTOR

  • PI3K/AKT

Drug/Treatment

  • Obatoclax

  • Thioridazine

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved